<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/61837">
      <dc:title>Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis</dc:title>
      <dc:creator>Jara Sosa, Lilian Elenea</dc:creator>
      <dc:creator>Clares Naveros, Beatriz</dc:creator>
      <dc:subject>Thermoreversible gel</dc:subject>
      <dc:subject>Poloxamer 407</dc:subject>
      <dc:subject>Amphotericin B</dc:subject>
      <dc:subject>Skin and vaginal mucosa</dc:subject>
      <dc:description>The present study was designed to develop a thermoreversible gel of Pluronic (P407)&#xd;
loaded amphotericin B (AmB-gel) for the dermal and vaginal treatment of candidiasis. P407 was&#xd;
used as a copolymer to exploit potential advantages related to increasing drug concentration in&#xd;
the tissue layer in order to provide a local effect. Parameters including internal structure, swelling,&#xd;
porosity, and short-term stability were determined. In addition, drug release profile and ex vivo&#xd;
skin and vaginal permeation studies were carried out. Antifungal efficacy was evaluated against&#xd;
strains of Candida spp. and atomic force microscopy (AFM) supported the results. The tolerance of&#xd;
AmB-gel was studied by evaluating biomechanical properties of skin and determining the irritation&#xd;
level in scarified rabbit skin supported by histological analysis. Results confirmed the development&#xd;
of a thermoreversible AmB-gel with high porosity exhibiting Newtonian behavior at 4 ºC and&#xd;
pseudoplasticity at 32 ºC as well as optimal stability for at least 90 days. The Amb-gel provided&#xd;
a sustained drug release following a Boltzmann sigmoidal model. Non permeation was observed&#xd;
in skin and vaginal mucosa, showing a high retained amount of AmB of 960.0 and 737.3 ug/g/cm2,&#xd;
respectively. In vitro antifungal efficacy showed that AmB-gel was more effective than Free-AmB&#xd;
in inhibiting strains of Candida spp. and these results were corroborated by AFM. Finally, tolerance&#xd;
studies showed that its application did not induce skin irritation nor alter its biophysical properties.&#xd;
Together, these results confirmed that AmB-gel could be proposed as a promising candidate for the&#xd;
clinical status in the treatment of skin and vaginal candidiasis.</dc:description>
      <dc:date>2020-05-06T12:03:31Z</dc:date>
      <dc:date>2020-05-06T12:03:31Z</dc:date>
      <dc:date>2019-07-03</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>Sosa, L., Calpena, A. C., Silva-Abreu, M., Espinoza, L. C., Rincón, M., Bozal, N., ... &amp; Clares, B. (2019). Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis. Pharmaceutics, 11(7), 312.</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/61837</dc:identifier>
      <dc:identifier>10.3390/pharmaceutics11070312</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>